AZ Sees China Digital Health Blossoming Post-Coronavirus
Executive Summary
'Internet hospitals', electronic prescriptions and online physician and patient education are likely to see increasing importance in a post-coronavirus China, says AstraZeneca's emerging markets head.
You may also be interested in...
Volume-Based Purchasing Looms Larger In Post-Coronavirus China
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
AstraZeneca: ‘Firing On All Cylinders’ In Q3
AstraZeneca beat market forecasts when posting its fifth successive quarter of revenue growth – but the UK drug maker warned that its sales in China will now slow down.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.